EA200602220A1 - Новое применение пептидных соединений для лечения амиотрофического бокового склероза - Google Patents

Новое применение пептидных соединений для лечения амиотрофического бокового склероза

Info

Publication number
EA200602220A1
EA200602220A1 EA200602220A EA200602220A EA200602220A1 EA 200602220 A1 EA200602220 A1 EA 200602220A1 EA 200602220 A EA200602220 A EA 200602220A EA 200602220 A EA200602220 A EA 200602220A EA 200602220 A1 EA200602220 A1 EA 200602220A1
Authority
EA
Eurasian Patent Office
Prior art keywords
peptide compounds
new application
treat amyotrophic
amyotrophic side
side sclerosis
Prior art date
Application number
EA200602220A
Other languages
English (en)
Russian (ru)
Inventor
Томас Штёр
Original Assignee
Шварц Фарма Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Шварц Фарма Аг filed Critical Шварц Фарма Аг
Publication of EA200602220A1 publication Critical patent/EA200602220A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EA200602220A 2004-06-09 2005-06-08 Новое применение пептидных соединений для лечения амиотрофического бокового склероза EA200602220A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57806304P 2004-06-09 2004-06-09
EP04013636A EP1604656A1 (en) 2004-06-09 2004-06-09 Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
PCT/EP2005/006169 WO2005120476A2 (en) 2004-06-09 2005-06-08 Novel use of peptide compounds for treating amyotrophic lateral sclerosis

Publications (1)

Publication Number Publication Date
EA200602220A1 true EA200602220A1 (ru) 2007-04-27

Family

ID=34925316

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200602220A EA200602220A1 (ru) 2004-06-09 2005-06-08 Новое применение пептидных соединений для лечения амиотрофического бокового склероза

Country Status (14)

Country Link
US (2) US20050277596A1 (https=)
EP (2) EP1604656A1 (https=)
JP (1) JP2008501753A (https=)
CN (1) CN1960720A (https=)
AT (1) ATE544449T1 (https=)
AU (1) AU2005251459A1 (https=)
BR (1) BRPI0511875A (https=)
CA (1) CA2565102A1 (https=)
EA (1) EA200602220A1 (https=)
MX (1) MXPA06014194A (https=)
TW (1) TW200701984A (https=)
UA (1) UA87843C2 (https=)
WO (1) WO2005120476A2 (https=)
ZA (1) ZA200608594B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60120104T2 (de) * 2001-03-20 2006-09-21 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
DK1243263T3 (da) * 2001-03-21 2003-03-17 Sanol Arznei Schwarz Gmbh Hidtil ukendt anvendelse af en klasse af peptidforbindelser til behandling af allodyni eller andre forskellige typer af kronisk- eller fantomsmerte
JP4664924B2 (ja) * 2003-12-02 2011-04-06 ウーツェーベー ファルマ ゲーエムベーハー 中枢神経因性疼痛の治療のためのペプチド化合物の新規使用
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (en) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in painful diabetic neuropathy
AU2005232395B2 (en) 2004-04-16 2010-09-09 Schwarz Pharma Ag Use of peptidic compounds for the prophylaxis and treatment of chronic headache
EP1604656A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
EP1604655A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
US7427601B2 (en) * 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
EA014055B1 (ru) * 2004-08-27 2010-08-30 Шварц Фарма Аг Применение пептидных соединений для лечения боли при раке кости, а также боли, вызванной химиотерапией и нуклеозидами
EP1642889A1 (en) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US7902401B2 (en) * 2006-12-14 2011-03-08 Nps Pharmaceuticals, Inc. Fluorinated compounds
CN101466390B (zh) * 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
EA019757B1 (ru) 2006-06-15 2014-06-30 ЮСиБи ФАРМА ГМБХ Фармацевтическая композиция с синергетическим противосудорожным эффектом
EP1873527A1 (en) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
CA2672494A1 (en) * 2006-12-14 2008-06-19 Nps Pharmaceuticals, Inc. Use of d-serine derivatives for the treatment of anxiety disorders
WO2009053070A1 (en) 2007-10-23 2009-04-30 Schwarz Pharma Ag Compounds for treating demyelination conditions
US8829033B2 (en) 2009-09-23 2014-09-09 The University Of North Carolina At Chapel Hill N-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents
WO2011101863A2 (en) 2010-02-19 2011-08-25 Cadila Healthcare Limited Extended release pharmaceutical compositions of lacosamide
EP2468261A1 (en) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
BR112013013525A2 (pt) 2010-12-02 2016-10-18 Ucb Pharma Gmbh formulação de liberação controlada sólida de lacosamida para administração oral, composição farmacêutica sólida, e, método para a prevenção, alívio e/ou tratamento de uma doença do sistema nervoso central
MA43532A (fr) 2015-12-30 2018-11-07 Adamas Pharmaceuticals Inc Méthodes et compositions destinés au traitement de troubles liés à des crises épileptiques
US11278634B1 (en) 2021-02-12 2022-03-22 Extrovis Ag Stable parenteral composition of lacosamide

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US101582A (en) * 1870-04-05 Improved refrigerator
US261204A (en) * 1882-07-18 Joel gadbuey
US227961A (en) * 1880-05-25 Envelope-fastener
US277596A (en) * 1883-05-15 Top-prop nut
DE2413125C2 (de) 1974-03-15 1983-06-30 Schering Ag, 1000 Berlin Und 4619 Bergkamen Indolylacetylaminosäurederivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneipräparate
DE2627069A1 (de) 1975-06-19 1977-01-20 Ajinomoto Kk Verfahren zur herstellung von substituierten schwefelhaltigen l-aminosaeuren
DE2735537A1 (de) 1977-08-06 1979-02-22 Troponwerke Gmbh & Co Kg Indolacetoxyacetylaminosaeurederivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JPS557242A (en) 1978-06-30 1980-01-19 Tanabe Seiyaku Co Ltd Phenethylamine derivative
FR2480747A1 (fr) 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
FR2489319A1 (fr) 1980-08-27 1982-03-05 Clin Midy Derives de l'acide amino-4 butyrique et les medicaments, actifs notamment sur le systeme nerveux central, en contenant
DE3134933A1 (de) 1981-09-03 1983-03-31 Hoechst Ag, 6230 Frankfurt "harnstoffderivate, verfahren zu ihrer herstellung und diese enthaltende medikamente sowie deren verwendung"
US5378729A (en) 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
ATE62222T1 (de) 1985-02-15 1991-04-15 Res Corp Technologies Inc Aminosaeure-derivate und ihre anwendung zur herstellung eines antikrampfmittels.
JPS61242589A (ja) 1985-04-22 1986-10-28 Mitsui Toatsu Chem Inc L−含硫アミノ酸の製造方法
PH24782A (en) 1985-10-24 1990-10-30 Sankyo Co Composition containing a penem or carbapenem antibiotic and the use of the same
NZ222045A (en) 1986-08-21 1989-10-27 Res Corp Technologies Inc From diamides up to tetrapeptides for use as anticanvulsants
CA2056911C (en) 1990-12-11 1998-09-22 Yuuichi Nagano Hiv protease inhibitors
JPH08505374A (ja) 1992-12-11 1996-06-11 チバ−ガイギー アクチェンゲゼルシャフト ベンズアゼピノン誘導体
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
JP4313435B2 (ja) 1995-07-24 2009-08-12 トラスティーズ オブ ボストン ユニバーシティー プレグネノロンサルフェート誘導体によるnmdaレセプター活性の抑制
DE19544687A1 (de) 1995-11-30 1997-06-05 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
GB9601724D0 (en) 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
US5773475A (en) * 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
DE19614533A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue alpha-Hydroxysäurederivate, ihre Herstellung und Verwendung
DE19614534A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
US6277825B1 (en) 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
DE19636046A1 (de) 1996-09-05 1998-03-12 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten
US6420429B1 (en) 1997-12-23 2002-07-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Brain targeted low molecular weight hydrophobic antioxidant compounds
US6048899A (en) * 1997-03-17 2000-04-11 Research Corporation Tech., Inc. Anticonvulsant enantiomeric amino acid derivatives
AU7937298A (en) 1997-07-08 1999-02-08 Ono Pharmaceutical Co. Ltd. Amino acid derivatives
DE19743142A1 (de) 1997-09-30 1999-04-01 Knoll Ag Pharmazeutische Kombinationspräparate
DE19743140A1 (de) 1997-09-30 1999-04-01 Knoll Ag Pharmazeutische Kombinationspräparate
DE19744799A1 (de) 1997-10-10 1999-04-15 Knoll Ag Pharmazeutische Kombinationspräparate
AU2266199A (en) 1997-10-31 1999-05-24 Basf Aktiengesellschaft New carboxylic acid derivatives, carrying amido side-chains; production and use as endothelin receptor antagonists
DE1073432T1 (de) 1998-04-14 2002-02-07 The General Hospital Corp., Boston Verwendung von glycinrezeptoragonisten und glycinaufnahmeinhibitoren zur behandlung neuropsychiatrischer beschwerden
GB9816228D0 (en) 1998-07-24 1998-09-23 Pfizer Ltd Isoquinolines
DE10029014A1 (de) 2000-06-15 2001-12-20 Univ Schiller Jena Urokinase-Hemmstoffe
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
AU2002224847A1 (en) 2000-11-21 2002-06-03 U C B, S.A. N-alkylated gaba compounds, processes for their preparation and their use as medicaments
DE60120104T2 (de) * 2001-03-20 2006-09-21 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
DK1243263T3 (da) * 2001-03-21 2003-03-17 Sanol Arznei Schwarz Gmbh Hidtil ukendt anvendelse af en klasse af peptidforbindelser til behandling af allodyni eller andre forskellige typer af kronisk- eller fantomsmerte
IL158412A0 (en) 2001-04-26 2004-05-12 Bristol Myers Squibb Co A method for increasing the compactability of an active ingredient and a process for producing a solid dosage form having a high active ingredient drug load
US7687080B2 (en) 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
DE10326303A1 (de) 2003-06-11 2004-12-30 Celares Gmbh Reagenzien zur Modifikation von Biopharmazeutika, deren Herstellung und Anwendung
US20050227961A1 (en) 2004-04-08 2005-10-13 Vela Pharmaceuticals, Inc. Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome
EP1604654A1 (en) 2004-05-18 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating dyskinesia
EP1604656A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)

Also Published As

Publication number Publication date
EP1755577B1 (en) 2012-02-08
AU2005251459A1 (en) 2005-12-22
JP2008501753A (ja) 2008-01-24
US7718161B2 (en) 2010-05-18
WO2005120476A3 (en) 2006-02-16
ATE544449T1 (de) 2012-02-15
EP1755577A2 (en) 2007-02-28
MXPA06014194A (es) 2007-03-12
BRPI0511875A (pt) 2008-01-15
WO2005120476A2 (en) 2005-12-22
CN1960720A (zh) 2007-05-09
CA2565102A1 (en) 2005-12-22
TW200701984A (en) 2007-01-16
ZA200608594B (en) 2008-04-30
EP1604656A1 (en) 2005-12-14
UA87843C2 (ru) 2009-08-25
US20050277596A1 (en) 2005-12-15
US20090018198A1 (en) 2009-01-15

Similar Documents

Publication Publication Date Title
EA200602220A1 (ru) Новое применение пептидных соединений для лечения амиотрофического бокового склероза
DE602005026508D1 (de) Monozyklische heterozyklen als kinase-hemmer
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
DK1414494T3 (da) Hæmmende antistoffer af HER3-aktivitet
DE60310991D1 (de) Phenylalaninderivate als hemmer der dipeptidyl peptidase zur behandlung oder prävention von diabetes
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
MA27548A1 (fr) Inhibiteurs heterocycliques beta-amines de la dipeptidyl peptidase pour le traitement ou la prevention du diabete.
UY26813A1 (es) Compuestos para tratar enfermedad de alzheimer
EA200802054A1 (ru) Ингибиторы фермента
MA29787B1 (fr) Traitement de maladies auto-immunes
MY146509A (en) Novel use of peptide compounds for treating essential tremor and other tremor syndromes
DK1453505T3 (da) Anvendelse af pramipexol til behandling af amyotrofisk lateral sklerose
EA200601912A1 (ru) Применение пептидных соединений для профилактики и лечения хронической головной боли
ATE390928T1 (de) Zusammensetzungen zur behandlung von hauterkrankungen
SI1973539T1 (sl) Uporaba benzokondenziranih heterocikličnih sulfamidnih derivatov za zdravljenje depresije
MA28176A1 (fr) Inhibiteurs de la forme mutante du kit
EA200701594A1 (ru) Лакозамид для дополнительной терапии
ATE439355T1 (de) 2 aminocarbonyl-substituierte piperazin- oder diaza-cyclische verbindungen als apoptose-protein-inhibitor (iap)-modulatoren
ATE550039T1 (de) Mittel zur behandlung von glomerulären erkrankungen
EA200601889A1 (ru) Лечение инфекционных заболеваний
EA200801244A1 (ru) Применение sdf-1 для лечения и/или профилактики неврологических заболеваний
SE0200198D0 (sv) New use
EA200400436A1 (ru) Медикаменты для профилактики и лечения бромидроза
EA200702336A1 (ru) ПРИМЕНЕНИЕ 24-норУДХК
DE602006020585D1 (de) Neue cysteinproteasehemmer und ihre therapeutische anwendung